Edition:
India

Cytosorbents Corp (CTSO.OQ)

CTSO.OQ on NASDAQ Stock Exchange Capital Market

7.50USD
8:38pm IST
Change (% chg)

$-0.05 (-0.66%)
Prev Close
$7.55
Open
$7.62
Day's High
$7.62
Day's Low
$7.37
Volume
9,859
Avg. Vol
46,800
52-wk High
$14.90
52-wk Low
$6.70

Latest Key Developments (Source: Significant Developments)

Cytosorbents Achieves Record Revenue And Product Sales Growth In 2018
Friday, 8 Mar 2019 

March 7 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS ACHIEVES RECORD REVENUE AND PRODUCT SALES GROWTH IN 2018.CYTOSORBENTS CORP - EXPECT Q1 2019 PRODUCT SALES TO EXCEED SALES REPORTED IN Q1 OF 2018.  Full Article

Cytosorbents Says Expanded Direct Sales Of Cytosorb For All Applications To Poland And Netherlands
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS - EXPANDED DIRECT SALES OF CYTOSORB FOR ALL APPLICATIONS TO POLAND, NETHERLANDS, & FOR CRITICAL CARE APPLICATIONS IN SWEDEN, DENMARK, NORWAY.CYTOSORBENTS CORP - COMPANY ESTABLISHED CYTOSORBENTS POLAND SP. Z.O.O., A WHOLLY-OWNED SUBSIDIARY OF CYTOSORBENTS EUROPE GMBH.  Full Article

Cytosorbents Sees FY 2018 Revenue Of About $22.3 Mln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS ISSUES STOCKHOLDER LETTER WITH PRELIMINARY 2018 FINANCIAL RESULTS.SEES FY 2018 REVENUE AT LEAST $22.3 MILLION.SEES Q4 2018 PRODUCT SALES OF APPROXIMATELY $5.4 MILLION.Q4 REVENUE VIEW $6.3 MILLION -- REFINITIV IBES DATA.FY2018 REVENUE VIEW $22.7 MILLION -- REFINITIV IBES DATA.  Full Article

Cytosorbents Awarded Up To $3 Mln In Funding
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS AWARDED UP TO $3M IN SBIR PHASE IIB BRIDGE FUNDING BY NIH/NHLBI.  Full Article

Cytosorbents Files For Mixed Shelf Of Up To $150 Million
Friday, 27 Jul 2018 

July 26 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING.  Full Article

Cytosorbents Sees Q4 2017 Revenue About $4.6 Million
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER.SEES Q4 2017 REVENUE ABOUT $4.6 MILLION.SEES FY 2017 REVENUE $15 MILLION.- WITH NEW TAX LAW, AND WITH SUBSTANTIAL FEDERAL NET OPERATING LOSSES "WE WILL NOT PAY FEDERAL INCOME TAX FOR A LONG TIME".  Full Article

U.S. FDA Approves Cytosorbents' Refresh 2 IDE Application With Conditions
Friday, 22 Dec 2017 

Dec 21 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS ACHIEVES KEY MILESTONE WITH FDA APPROVAL OF THE U.S. REFRESH 2 PIVOTAL CARDIAC SURGERY TRIAL IDE APPLICATION.U.S. FDA GRANTED APPROVAL OF REFRESH 2 INVESTIGATIONAL DEVICE EXEMPTION APPLICATION, WITH CONDITIONS.CONDITIONS RELATE TO REQUESTED CLARIFICATIONS, CHANGES TO PATIENT CONSENT FORM & INSTRUCTIONS FOR USE DOCUMENT.  Full Article

Cytosorbents posts Q3 revenue of $3.8 mln
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Cytosorbents Corp :Cytosorbents continues strong trajectory of growth in the third quarter 2017.Total Q3 2017 revenues increased 59% to $3.8 million​.  Full Article